Geron Corporation reported full-year 2025 net product revenue of $184 million from RYTELO, with fourth-quarter sales reaching $48 million. The biopharmaceutical company's annual operating expenses totaled $255 million, in line with previous guidance, while the company concluded the year with $401 million in cash and cash equivalents.
Looking ahead to 2026, Geron projects RYTELO revenue between $220 million and $240 million, signaling anticipated growth in the drug's commercial performance. The company attributed the expected revenue increase to continued domestic market expansion and emerging international opportunities for the telomerase inhibitor.
In December 2025, Geron implemented a workforce reduction of approximately one-third as part of a strategic restructuring effort. The company remains focused on optimizing operational efficiency while advancing its U.S. commercial initiatives and evaluating geographic expansion possibilities for RYTELO.